Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Scientists clarify mechanism of defective immune defense in G6PD patients

Favism is a common hereditary disease, affecting around 400 million people worldwide. It is caused by a lack of the enzyme glucose-6-phosphate dehydrogenase (G6PD).

26 Jul 2016

Male hormones can reverse biological drivers of aging, study shows

Telomerase, an enzyme naturally found in the human organism, is the closest of all known substances to a "cellular elixir of youth." In a recent study, Brazilian and US researchers show that sex hormones can stimulate production of this enzyme.

26 Jul 2016

Blood cancer is associated with considerably higher healthcare costs than other cancers

Health economics studies, published today in The Lancet Haematology, report that the cost of treating blood cancers is twice that for treating other cancers. This is largely because they require more complex treatment regimens that necessitate longer hospital stays.

22 Jul 2016

Blood utilization practice guidelines can save millions of dollars, reduce blood wastage

Improving the processes of ordering, transporting, and storing blood can save millions of dollars and drastically reduce blood wastage, reported a research team from one academic medical center after implementing institutional initiatives to address blood management.

18 Jul 2016

Critical evaluation of EKF Diagnostics’ Quo-Test analyzer released

EKF, announces release of a significant critical evaluation of the Quo-Test analyzer carried out by the European Reference Laboratory for Gylcohemoglobin.

From EKF Diagnostics 11 Jul 2016

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year.

6 Jul 2016

Anaemia in heart failure may impact prognosis

Anaemia is common in patients with heart failure, regardless of the underlying phenotype, and is often associated with iron deficiency, UK researchers report.

6 Jul 2016

Scientists discover new way to predict risk for delayed recovery in children with AML

The chemotherapy treatments necessary to treat Acute Myeloid Leukemia (AML) in children can be grueling on the body, and can cause health-related complications during therapy, as well as long down the road after remission.

1 Jul 2016

New computer model shows how spleen filters misshapen red blood cells

Researchers, led by Carnegie Mellon University President Subra Suresh and MIT Principal Research Scientist Ming Dao, have created a new computer model that shows how tiny slits in the spleen prevent old, diseased or misshapen red blood cells from re-entering the bloodstream.

28 Jun 2016

Scientists explore effects of physiological fluid shear on dangerous type of Salmonella

Once inside the human body, infectious microbes like Salmonella face a fluid situation. They live in a watery world, surrounded by liquid continually flowing over and abrading their cell surfaces--a property known as fluid shear.

9 Jun 2016

Scientists develop non-toxic transplantation procedure using antibodies to target blood stem cells in mice

Harvard Stem Cell Institute scientists have taken the first steps toward developing a treatment that would make bone marrow - blood stem cell - transplantation safer and, as a result, more widely available to the millions of people living with blood disorders like sickle cell anemia, thalassemia, and AIDS.

7 Jun 2016

Targeted therapy rucaparib shows promise in treating pancreatic cancer patients with BRCA mutation

The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation, according to results from a phase II clinical study presented by Susan M. Domchek, MD, executive director of the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, at the American Society of Clinical Oncology Annual Meeting.

6 Jun 2016

Nivolumab drug shows better response rate in metastatic bladder cancer patients

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.

6 Jun 2016

The National MDS Study aims to identify causes, genetic makeup of fatal blood diseases

The National Myelodysplastic Syndromes Natural History Study is underway, the ECOG-ACRIN Cancer Research Group and its collaborators announced today.

26 May 2016

Positive effects of good nutrition linked to child's social behavior, development

Proper nutrition during childhood can positively affect a child's social behaviors and development.

11 May 2016

New article reviews guidelines for folic acid supplementation in pregnancy

Future Science Group today announced the publication of a new article in Future Science OA, reviewing national and international guidelines for folic acid supplementation, and analyzing its potential risks and benefits in terms of maternal and fetal outcomes.

9 May 2016

Minihepcidins may potentially treat serious genetic blood diseases in children, adults

New research suggests that synthetic peptides called minihepcidins may potentially treat two serious genetic blood diseases in children and adults. Although those diseases, beta-thalassemia and polycythemia vera, have opposite effects on red blood cell production, treating animals with minihepcidin helps to restore normal levels of red blood cells and reduces spleen enlargement. It also controls the accumulation of excess levels of iron in beta-thalassemia that often causes severe toxic effects.

9 May 2016

Globin gene transfer to treat beta-thalassemias shows promise in first clinical trial

Promising results from the first clinical trials of globin gene transfer to treat beta-thalassemias-inherited forms of anemia-have eliminated the need for blood transfusions in some individuals.

6 May 2016

Experimental drug ozanimod moderately effective in treatment of ulcerative colitis

Researchers at University of California San Diego School of Medicine have shown that ozanimod (RPC1063), a novel drug molecule, is moderately effective in the treatment of ulcerative colitis. Results of the Phase II clinical trial will appear in the May 5 issue of the New England Journal of Medicine.

5 May 2016

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.

4 May 2016